Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.55% 0.02% 1.503B 39528.27
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% -- -161.24M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 16.38 yrs
David McGarel 16.38 yrs
Jon Erickson 16.38 yrs
Roger Testin 16.38 yrs
Stan Ueland 15.99 yrs
Chris Peterson 6.63 yrs
Erik Russo 1.84 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 73
-161.24M
-3.207B Category Low
8.937B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of November 30, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of December 02, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
-3.59%
-1.80%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
21.82%
-14.12%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
1.54%
-4.47%
--
-25.62%
13.57%
-20.62%
24.19%
36.52%
-19.14%
-36.72%
--
--
--
--
--
65.01%
-0.23%
-29.84%
--
--
--
--
--
--
-14.21%
-23.76%
As of December 02, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-2-22) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 15.28
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of November 28, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of November 28, 2022

Asset Allocation

As of November 28, 2022.
Type % Net % Long % Short
Cash 0.01% Upgrade Upgrade
Stock 99.99% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Moderna Inc 4.11% 182.35 0.48%
Grifols SA ADR 4.02% 8.41 1.20%
Exact Sciences Corp 3.88% 46.36 0.78%
Gilead Sciences Inc 3.81% 89.03 1.29%
IQVIA Holdings Inc 3.69% 217.73 -1.28%
Mettler-Toledo International Inc 3.69% 1486.10 -0.28%
United Therapeutics Corp 3.66% 278.55 1.07%
Charles River Laboratories International Inc 3.63% 222.66 -1.56%
Genmab A/S ADR 3.59% 47.06 1.44%
Bio-Techne Corp 3.58% 84.69 -1.99%

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 16.38 yrs
David McGarel 16.38 yrs
Jon Erickson 16.38 yrs
Roger Testin 16.38 yrs
Stan Ueland 15.99 yrs
Chris Peterson 6.63 yrs
Erik Russo 1.84 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-2-22) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 15.28
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of November 28, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of November 28, 2022

Fund Details

Key Dates
Inception Date 6/19/2006
Last Annual Report Date 12/31/2021
Last Prospectus Date 5/2/2022
Attributes
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

Top Portfolio Holders

0 of 0